JP4722481B2 - リポソーム製造方法および装置 - Google Patents

リポソーム製造方法および装置 Download PDF

Info

Publication number
JP4722481B2
JP4722481B2 JP2004516377A JP2004516377A JP4722481B2 JP 4722481 B2 JP4722481 B2 JP 4722481B2 JP 2004516377 A JP2004516377 A JP 2004516377A JP 2004516377 A JP2004516377 A JP 2004516377A JP 4722481 B2 JP4722481 B2 JP 4722481B2
Authority
JP
Japan
Prior art keywords
lipid
solution
organic
therapeutic agent
vesicles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004516377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538967A (ja
Inventor
イアン マクラックラン，
ロイド ジェフス，
ローン アール． パルマー，
コーリー ジースブレッチ，
Original Assignee
プロティバ バイオセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4722481(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by プロティバ バイオセラピューティクス リミテッド filed Critical プロティバ バイオセラピューティクス リミテッド
Publication of JP2005538967A publication Critical patent/JP2005538967A/ja
Application granted granted Critical
Publication of JP4722481B2 publication Critical patent/JP4722481B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004516377A 2002-06-28 2003-06-30 リポソーム製造方法および装置 Expired - Lifetime JP4722481B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39288702P 2002-06-28 2002-06-28
US60/392,887 2002-06-28
PCT/CA2003/000941 WO2004002453A1 (en) 2002-06-28 2003-06-30 Method and apparatus for producing liposomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010129251A Division JP5192515B2 (ja) 2002-06-28 2010-06-04 リポソーム製造方法および装置

Publications (2)

Publication Number Publication Date
JP2005538967A JP2005538967A (ja) 2005-12-22
JP4722481B2 true JP4722481B2 (ja) 2011-07-13

Family

ID=30000947

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2004516377A Expired - Lifetime JP4722481B2 (ja) 2002-06-28 2003-06-30 リポソーム製造方法および装置
JP2010129251A Expired - Lifetime JP5192515B2 (ja) 2002-06-28 2010-06-04 リポソーム製造方法および装置
JP2013001800A Withdrawn JP2013067657A (ja) 2002-06-28 2013-01-09 リポソーム製造方法および装置
JP2016135694A Withdrawn JP2016172778A (ja) 2002-06-28 2016-07-08 リポソーム製造方法および装置
JP2016154302A Pending JP2016199585A (ja) 2002-06-28 2016-08-05 リポソーム製造方法および装置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010129251A Expired - Lifetime JP5192515B2 (ja) 2002-06-28 2010-06-04 リポソーム製造方法および装置
JP2013001800A Withdrawn JP2013067657A (ja) 2002-06-28 2013-01-09 リポソーム製造方法および装置
JP2016135694A Withdrawn JP2016172778A (ja) 2002-06-28 2016-07-08 リポソーム製造方法および装置
JP2016154302A Pending JP2016199585A (ja) 2002-06-28 2016-08-05 リポソーム製造方法および装置

Country Status (10)

Country Link
US (10) US7901708B2 (https=)
EP (3) EP1519714B1 (https=)
JP (5) JP4722481B2 (https=)
AT (1) ATE485031T1 (https=)
AU (2) AU2003245160B2 (https=)
CA (1) CA2491164C (https=)
DE (1) DE60334618D1 (https=)
DK (1) DK1519714T3 (https=)
ES (1) ES2354607T3 (https=)
WO (1) WO2004002453A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067657A (ja) * 2002-06-28 2013-04-18 Protiva Biotherapeutics Ltd リポソーム製造方法および装置

Families Citing this family (543)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US9198645B2 (en) * 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US8715591B2 (en) * 2004-07-21 2014-05-06 The United States of America, as represented by the Secretary of Commerce, The National Institute of Standards and Technology Microfluidic apparatus to control liposome formation
EP1802277B1 (de) * 2004-10-18 2010-01-13 Polymun Scientific Immunbiologische Forschung GmbH Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CA2605068A1 (en) 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
CN101267805A (zh) * 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
EP1934348B1 (en) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2012750B1 (en) * 2006-04-06 2018-02-21 Insmed Incorporated Methods for coacervation induced liposomal encapsulation and formulations thereof
KR101128639B1 (ko) * 2006-11-17 2012-03-26 현대중공업 주식회사 휠식 건설기계의 핸들 및 조이스틱 조향을 위한유압제어장치
EP2117304A4 (en) * 2007-02-07 2011-08-24 Gradalis Inc METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
WO2008109432A2 (en) 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
EP3494964B1 (en) * 2007-05-14 2021-04-07 Konica Minolta Holdings, Inc. Liposome and method for producing liposome
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
ES2535419T3 (es) 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
EP2281041B1 (en) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Silencing of csn5 gene expression using interfering rna
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
JP2012505913A (ja) * 2008-10-16 2012-03-08 マリーナ バイオテック，インコーポレイテッド 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物
JP2012507565A (ja) 2008-10-30 2012-03-29 グオ・ペイシュエン Ｄｎａのシークエンシング及び他の用途のための、膜に組み込まれたウイルスｄｎａパッケージングモータタンパク質コネクタバイオセンサ
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
CN107028886A (zh) 2009-11-04 2017-08-11 不列颠哥伦比亚大学 含有核酸的脂质粒子及相关的方法
ES2691276T3 (es) * 2009-11-30 2018-11-26 Shiseido Company, Ltd. Polimerosoma y procedimiento para su producción
EP3318248B1 (en) 2009-12-01 2019-04-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
DK2561077T3 (en) 2010-04-23 2016-08-01 Arrowhead Res Corp Organic compositions for the treatment of beta-ENaC-related diseases
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2012006101A2 (en) 2010-06-28 2012-01-12 The General Hospital Corporation Blood substitutes and uses thereof
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
JP5952197B2 (ja) * 2011-01-19 2016-07-13 協和発酵キリン株式会社 標的遺伝子の発現を抑制する組成物
CA2864394C (en) 2011-03-02 2021-10-19 Jack Roth A method of predicting a response to a tusc2 therapy
BR112013024663A2 (pt) * 2011-03-25 2016-12-20 Terumo Corp composição de lipossomas de liberação controlada de longa duração e método para produção da mesma
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2013154295A (ru) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA3185394A1 (en) 2011-09-02 2013-03-07 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
WO2013059922A1 (en) 2011-10-25 2013-05-02 The University Of British Columbia Limit size lipid nanoparticles and related methods
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3485875A1 (en) * 2011-11-04 2019-05-22 Nitto Denko Corporation Single use system for sterelily producing lipid-nucleic acid particles
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
WO2013086354A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
AU2012347605B2 (en) 2011-12-07 2017-09-21 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP2802658A2 (en) 2012-01-09 2014-11-19 Novartis AG Rnai agents to treat beta-catenin related diseases
EP2817287B1 (en) 2012-02-24 2018-10-03 Arbutus Biopharma Corporation Trialkyl cationic lipids and methods of use thereof
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
EA201492004A1 (ru) 2012-05-02 2015-08-31 Новартис Аг Органические композиции для лечения kras-ассоциированных заболеваний
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
KR101493961B1 (ko) * 2012-05-16 2015-02-17 한국생명공학연구원 압출공정 없이 핵산 함유 나노 리포솜을 제조하는 방법
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
EP2874605A1 (en) 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
JPWO2014046191A1 (ja) 2012-09-21 2016-08-18 テルモ株式会社 局所麻酔薬持続徐放性リポソーム製剤
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN105247051A (zh) 2013-02-28 2016-01-13 箭头研究公司 治疗epas1相关疾病的有机组合物
BR112015022855A2 (pt) 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
CN105142614A (zh) 2013-03-14 2015-12-09 迪克纳制药公司 用于配制阴离子试剂的方法
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3388834B1 (en) 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
CN105143456A (zh) 2013-03-15 2015-12-09 不列颠哥伦比亚大学 用于转染的脂质纳米粒子和相关方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
JP6620093B2 (ja) 2013-07-23 2019-12-11 アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ メッセンジャーｒｎａを送達するための組成物及び方法
US10195291B2 (en) 2013-09-24 2019-02-05 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのｍＲＮＡ療法
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
AU2014340149B2 (en) 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
US9636034B2 (en) 2013-10-23 2017-05-02 Verily Life Sciences Llc Non-invasive analyte detection system with modulation source
US10542918B2 (en) 2013-10-23 2020-01-28 Verily Life Sciences Llc Modulation of a response signal to distinguish between analyte and background signals
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
AR094658A1 (es) * 2014-01-14 2015-08-19 Fast Rehydration Llc Formulación de sales de rehidratación liposomal
US10751283B2 (en) 2014-01-14 2020-08-25 Capability Building, Inc. Liposomal rehydration salt formulation and associated methods of use
KR102396026B1 (ko) * 2014-01-21 2022-05-09 안자리움 바이오사이언시스 아게 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
JP6557722B2 (ja) 2014-05-30 2019-08-07 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 核酸の送達のための生分解性脂質
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
EP3736334A1 (en) 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
US9765333B2 (en) 2014-08-21 2017-09-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing marburg virus gene expression
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3201338B1 (en) 2014-10-02 2021-11-03 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
JP6767976B2 (ja) 2014-12-05 2020-10-14 トランスレイト バイオ， インコーポレイテッド 関節疾患の治療のためのメッセンジャーｒｎａ治療法
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US9861710B1 (en) 2015-01-16 2018-01-09 Verily Life Sciences Llc Composite particles, methods, and in vivo diagnostic system
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
WO2016149508A1 (en) 2015-03-19 2016-09-22 Shire Human Genetic Therapies, Inc. Mrna therapy for pompe disease
CA2977827C (en) 2015-03-19 2023-10-17 University Of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
EP3275448B1 (en) 2015-03-24 2025-10-29 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
EP3302525A2 (en) 2015-06-05 2018-04-11 Novartis AG Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的ｃｒｉｓｐｒ酶突變
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
AU2016279077A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
JP6997704B2 (ja) 2015-10-14 2022-02-04 トランスレイト バイオ， インコーポレイテッド 生産性向上のためのｒｎａ関連酵素の修飾
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
CN116814590A (zh) 2015-10-22 2023-09-29 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
HRP20230209T1 (hr) 2015-10-28 2023-04-14 Acuitas Therapeutics Inc. Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
KR102787119B1 (ko) 2015-11-30 2025-03-27 듀크 유니버시티 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
EP3825400B1 (en) 2016-04-08 2024-12-25 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
EP3469074B1 (en) 2016-06-13 2020-12-09 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
CN109642231A (zh) 2016-06-17 2019-04-16 博德研究所 Vi型crispr直向同源物和系统
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
CN109563511A (zh) 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
CN106074402A (zh) * 2016-07-28 2016-11-09 浙江美保龙生物技术有限公司 一种猪细小病毒脂质体稀释液冻干制品及其制备方法
EP4485466A3 (en) 2016-08-17 2025-04-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
CN106074404A (zh) * 2016-08-17 2016-11-09 浙江美保龙生物技术有限公司 一种猪繁殖与呼吸综合征病毒脂质体稀释液冻干制品及其制备方法
EP3500294A4 (en) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018047148A1 (en) 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
JP7041136B2 (ja) 2016-10-12 2022-03-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔｕｓｃ２免疫療法のための方法および組成物
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3532103B1 (en) 2016-10-26 2025-12-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3535396A1 (en) 2016-11-01 2019-09-11 Novartis AG Methods and compositions for enhancing gene editing
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
AU2017378427A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
JP2020511141A (ja) 2017-03-15 2020-04-16 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
MX2019012280A (es) 2017-04-11 2020-01-23 Arbutus Biopharma Corp Composiciones dirigidas.
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
IL271275B1 (en) 2017-06-13 2026-04-01 Flagship Pioneering Innovations V Inc Preparations containing croons and their uses
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
WO2019027055A1 (ja) 2017-08-04 2019-02-07 協和発酵キリン株式会社 核酸含有脂質ナノ粒子
CA3073020A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
EP4501322A3 (en) 2017-08-17 2025-04-16 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
IT201700099627A1 (it) * 2017-09-06 2019-03-06 Anna Angela Barba Produzione di vettori nano-liposomiali incapsulanti ferro altamente biodisponibile con tecnica in continuo.
KR20240161202A (ko) 2017-09-11 2024-11-12 애로우헤드 파마슈티컬스 인코포레이티드 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
WO2019135816A2 (en) 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
WO2019089803A1 (en) 2017-10-31 2019-05-09 The Broad Institute, Inc. Methods and compositions for studying cell evolution
US11638695B2 (en) 2017-11-01 2023-05-02 Osaka University Development of method and apparatus for producing lipid particles having desired particle diameter
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
CN109893664B (zh) * 2017-12-11 2022-03-11 四川大学 一种阳离子脂质纳米颗粒/dna复合物及其制备方法
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
US11167043B2 (en) 2017-12-20 2021-11-09 Translate Bio, Inc. Composition and methods for treatment of ornithine transcarbamylase deficiency
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019139997A1 (en) 2018-01-09 2019-07-18 Trucode Gene Repair, Inc. Polymer-based nanoparticles, related formulation methods, and apparatus
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
MA52074A (fr) 2018-03-19 2021-01-27 Bayer Healthcare Llc Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
MY208145A (en) 2018-06-18 2025-04-18 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
JP2021532815A (ja) 2018-08-07 2021-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Ｃａｓ１２ｂ酵素およびシステム
EP3842538A4 (en) 2018-08-10 2022-06-08 Kyoto University METHOD OF TRANSFECTION INTO CARDIOMYOCYTES USING CATIONIC LIPID
US12479791B2 (en) 2018-08-10 2025-11-25 Takeda Pharmaceutical Company Limited Cationic lipid
US12421507B2 (en) 2018-08-20 2025-09-23 The Broad Institute, Inc. Methods and compositions for optochemical control of CRISPR-CAS9
KR102950141B1 (ko) 2018-08-24 2026-04-07 트랜슬레이트 바이오 인코포레이티드 전령 rna의 정제 방법
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
EP3856757A4 (en) 2018-09-28 2022-06-29 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
CA3114435A1 (en) 2018-10-01 2020-04-09 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
EP3876999A4 (en) 2018-11-09 2022-08-31 Arbutus Biopharma Corporation NEGATIVELY CHARGED PEG-LIPID CONJUGATES
KR20210105889A (ko) 2018-11-09 2021-08-27 아뷰터스 바이오파마 코포레이션 지질 나노입자 제제
AU2019376006A1 (en) 2018-11-09 2021-06-03 Arbutus Biopharma Corporation Cationic lipids containing silicon
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
CN113710799B (zh) 2018-11-28 2024-11-12 克里斯珀医疗股份公司 用于在LNP中使用的编码CAS9的优化mRNA
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
SG11202105577TA (en) 2019-01-09 2021-06-29 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
SG11202110036RA (en) * 2019-03-19 2021-10-28 Arcturus Therapeutics Inc Method of making lipid-encapsulated rna nanoparticles
EP3711749A1 (en) 2019-03-19 2020-09-23 Polymun Scientific Immunbiologische Forschung GmbH Method of making lipid nanoparticles
EP3947646A1 (en) 2019-04-05 2022-02-09 Precision BioSciences, Inc. Methods of preparing populations of genetically-modified immune cells
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN114026228A (zh) 2019-05-07 2022-02-08 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
US20220273715A1 (en) 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CN114901253A (zh) 2019-08-14 2022-08-12 爱康泰生治疗公司 用于递送核酸的改进的脂质纳米颗粒
WO2021046265A1 (en) 2019-09-06 2021-03-11 Generation Bio Co. Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
CA3155015A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031662A1 (en) 2019-09-20 2022-07-27 Translate Bio, Inc. Mrna encoding engineered cftr
JP2023502576A (ja) 2019-11-22 2023-01-25 ジェネレーション バイオ カンパニー イオン化可能な脂質およびそれらのナノ粒子組成物
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
KR20230004456A (ko) 2020-03-04 2023-01-06 리제너론 파아마슈티컬스, 인크. 면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
EP4121018A4 (en) 2020-03-17 2024-07-03 Genevant Sciences Gmbh CATIONIC LIPIDS FOR LIPID DNANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLA CELLS
JP7746280B2 (ja) 2020-03-27 2025-09-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
IL296781A (en) 2020-03-30 2022-11-01 BioNTech SE Rna compositions targeting claudin-18.2
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
CN115996707A (zh) 2020-04-20 2023-04-21 德克萨斯大学系统董事会 生物活性干粉组合物及其制造和使用方法
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
CA3172171A1 (en) 2020-05-12 2021-11-18 Victor Bartsevich Treatment of retinitis pigmentosa using improved engineered meganucleases
US12188060B2 (en) 2020-05-15 2025-01-07 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
EP3915544A1 (en) * 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Method for producing a liposome dispersion
IL299094A (en) 2020-06-15 2023-02-01 Res Inst Nationwide Childrens Hospital Administration of an adeno-associated virus vector for muscular dystrophies
WO2025056938A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
WO2022040435A1 (en) 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
CN112206726A (zh) * 2020-09-04 2021-01-12 仲恺农业工程学院 海藻酸钠/乳脂粉昆虫病毒微胶囊及其制备方法
IL301253A (en) 2020-09-13 2023-05-01 Arcturus Therapeutics Inc As a mass of large RNA lipid nanoparticles
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2022076547A1 (en) 2020-10-07 2022-04-14 Precision Biosciences, Inc. Lipid nanoparticle compositions
EP4228658A4 (en) 2020-10-14 2025-02-19 George Mason Research Foundation, Inc. IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
AU2021403156A1 (en) 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
IL305353A (en) 2021-02-26 2023-10-01 Ethris Gmbh Formulations for aerosol formation and aerosols for the delivery of nucleic acid
EP4059491A1 (de) 2021-03-17 2022-09-21 Evonik Operations GmbH Vorrichtung und verfahren zur herstellung von nanocarriern und/oder nanoformulierungen
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
AU2022262778A1 (en) 2021-04-22 2023-11-30 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
WO2022226305A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Engineered meganucleases that target human mitochondrial genomes
EP4352215A1 (en) 2021-06-11 2024-04-17 LifeEDIT Therapeutics, Inc. Rna polymerase iii promoters and methods of use
AU2022291742A1 (en) 2021-06-14 2023-12-21 Generation Bio Co. Cationic lipids and compositions thereof
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CA3227103A1 (en) 2021-07-30 2023-02-02 Matthew P. GEMBERLING Compositions and methods for modulating expression of frataxin (fxn)
US20240252684A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CN118317944A (zh) 2021-09-14 2024-07-09 雷纳嘉德医疗管理公司 非环状脂质及其使用方法
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
EP4426828A1 (en) 2021-11-01 2024-09-11 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
JP2024542188A (ja) 2021-11-16 2024-11-13 セイル バイオメディシンズ インコーポレイテッド 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
JP2024542260A (ja) 2021-11-22 2024-11-13 セイル バイオメディシンズ インコーポレイテッド 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20250059131A1 (en) 2021-12-16 2025-02-20 Acuitas Therapeutics, Inc. Fluorinated cationic lipids for use in lipid nanoparticles
EP4700017A2 (en) 2021-12-16 2026-02-25 Acuitas Therapeutics Inc. Fluorinated cationic lipids for use in lipid nanoparticles
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
PE20241621A1 (es) 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos
AU2022420615A1 (en) 2021-12-22 2024-07-04 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
EP4452928A1 (en) 2021-12-23 2024-10-30 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US20250345416A1 (en) 2022-01-27 2025-11-13 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
KR20240146674A (ko) 2022-01-31 2024-10-08 제네반트 사이언시즈 게엠베하 지질 나노입자를 위한 이온화 가능한 양이온성 지질
CN118900701A (zh) 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023178182A1 (en) 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
KR20240166554A (ko) 2022-03-25 2024-11-26 세일 바이오메디슨스, 인크. 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
WO2023184038A1 (en) 2022-04-01 2023-10-05 Nanovation Therapeutics Inc. Mrna delivery method and composition thereof
IL316038A (en) 2022-04-04 2024-11-01 Univ California Preparations and methods for genetic complementation
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023198828A1 (en) 2022-04-13 2023-10-19 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
US20250346905A1 (en) 2022-05-05 2025-11-13 The Board Of Trustees Of The Leland Stanford Junior University INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
JP2025522297A (ja) 2022-05-25 2025-07-15 ビオンテック エスエー サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
GB202208022D0 (en) 2022-05-31 2022-07-13 Sisaf Ltd Therapeutic compounds and compositions
EP4536197A1 (en) 2022-06-07 2025-04-16 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
IL317874A (en) 2022-06-24 2025-02-01 Tune Therapeutics Inc Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
WO2024006863A1 (en) 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CA3261865A1 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
GB202210794D0 (en) 2022-07-22 2022-09-07 Sisaf Ltd Lipid formulations
EP4569093A1 (en) 2022-08-12 2025-06-18 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
KR20250077608A (ko) 2022-08-19 2025-05-30 튠 쎄라퓨틱스, 인코포레이티드 표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
US20260060926A1 (en) 2022-08-31 2026-03-05 Sail Biomedicines, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
JP2025530171A (ja) 2022-09-07 2025-09-11 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤で使用するための脂質
EP4584011A1 (en) 2022-09-08 2025-07-16 Evonik Operations GmbH Improved nanocarrier manufacturing
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025533527A (ja) 2022-09-23 2025-10-07 ビオンテック・ソシエタス・エウロパエア Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
IL319704A (en) 2022-09-23 2025-05-01 Nchroma Bio Inc Compositions and methods for epigenetic regulation of HBV gene expression
WO2024074376A1 (en) 2022-09-27 2024-04-11 Resolution Therapeutics Limited Therapeutic macrophages
WO2024074634A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
IL320459A (en) 2022-10-27 2025-06-01 Pfizer Rna molecules encoding rsv-f and vaccines containing them
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
US20250367129A1 (en) 2022-11-04 2025-12-04 Pfizer Inc. Lipid Compounds and Uses Thereof
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
AU2023406303A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
EP4626400A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
WO2024119074A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024119103A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびｒｓｖに対する免疫原性組成物
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
EP4642797A1 (en) 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
EP4649087A2 (en) 2023-01-11 2025-11-19 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
WO2024154052A1 (en) 2023-01-16 2024-07-25 Pfizer Inc. Immunogenic compositions and methods of inducing an immune response against varicella zoster virus
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
EP4658636A1 (en) 2023-01-31 2025-12-10 Pfizer Inc. Lipid compounds and uses thereof
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024194756A1 (en) 2023-03-17 2024-09-26 Pfizer Inc. Modulating the innate immunity of rna
EP4698651A1 (en) 2023-04-19 2026-02-25 Gradalis, Inc. Compositions and methods for modulating sialic acid production and treating hereditary inclusion body myopathy (hibm)
WO2024228044A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
WO2024228150A1 (en) 2023-05-03 2024-11-07 BioNTech SE Optimized csp variants and related methods
CN121443580A (zh) 2023-05-05 2026-01-30 爱康泰生治疗公司 用于脂质纳米颗粒制剂的脂质
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2024238700A1 (en) 2023-05-15 2024-11-21 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2024240962A1 (en) 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250000960A1 (en) 2023-06-14 2025-01-02 Pfizer Inc. Polynucleotide compositions and uses thereof
AU2024305649A1 (en) 2023-06-16 2026-01-08 Acuitas Therapeutics, Inc. Mixed amide ester containing lipids for use in lipid nanoparticles
KR20260032546A (ko) 2023-06-16 2026-03-09 아퀴타스 테라퓨틱스 인크. 아미드 포함 지질
EP4727913A1 (en) 2023-06-16 2026-04-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticles
EP4736848A1 (en) 2023-06-28 2026-05-06 Shanghai Regenelead Therapies Co., Ltd. Pharmaceutical composition containing cationic lipid and use thereof
CN121443279A (zh) 2023-06-28 2026-01-30 环球生命科学解决方案加拿大有限公司 用于细胞疗法的脂质纳米颗粒制剂和相关方法
WO2025017476A1 (en) 2023-07-19 2025-01-23 Pfizer Inc. Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
WO2025024324A1 (en) 2023-07-21 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
IL325865A (en) 2023-07-21 2026-03-01 BioNTech SE Compositions for administering Plasmodium antigens and related methods
WO2025024337A1 (en) 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025022367A2 (en) 2023-07-27 2025-01-30 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法
WO2025027089A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thiolipids and uses thereof
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
WO2025030097A2 (en) 2023-08-03 2025-02-06 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025030154A1 (en) 2023-08-03 2025-02-06 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
CN121729225A (zh) 2023-08-25 2026-03-24 埃泽瑞斯公司 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025051994A1 (en) 2023-09-07 2025-03-13 Coave Therapeutics Ionizable lipid nanoparticles
WO2025054556A1 (en) 2023-09-07 2025-03-13 BioNTech SE Rna compositions for delivery of mpox antigens and related methods
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025057088A1 (en) 2023-09-11 2025-03-20 BioNTech SE Rna compositions for delivery of incretin agents
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025057115A2 (en) 2023-09-15 2025-03-20 Pfizer Inc. Methods and compositions for continuous production of nucleic acids
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
AU2024352437A1 (en) 2023-09-27 2026-03-19 Resolution Therapeutics Limited Therapeutic macrophages
AU2024357861A1 (en) 2023-10-12 2026-04-23 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025083619A1 (en) 2023-10-18 2025-04-24 Life Edit Therapeutics, Inc. Rna-guided nucleases and acive fragments and variants thereof and methods of use
WO2025088570A1 (en) 2023-10-26 2025-05-01 Crispr Therapeutics Ag Ionizable lipids and ionizable lipid nanoparticles
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
US20250161227A1 (en) 2023-11-17 2025-05-22 Acuitas Therapeutics, Inc. Pegylated lipids
WO2025114520A1 (en) 2023-12-01 2025-06-05 Coave Therapeutics Ionizable lipid nanoparticles
WO2025128696A1 (en) 2023-12-12 2025-06-19 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025126019A1 (en) 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules
WO2025132122A1 (en) 2023-12-13 2025-06-26 Berlin Institute Of Health Methods of delivering therapeutics using lipid nanoparticles
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025126113A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025126118A1 (en) 2023-12-15 2025-06-19 Pfizer Inc. Lipid compounds and uses thereof
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025133105A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134046A1 (en) 2023-12-22 2025-06-26 Pfizer Inc. Methods and vaccine compositions for lyme disease
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025174908A1 (en) 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
WO2025174858A1 (en) 2024-02-15 2025-08-21 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025184508A1 (en) 2024-03-01 2025-09-04 Acuitas Therapeutics, Inc. Materials and methods for encapsulating therapeutics in lipid nanoparticles
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
US20260061042A1 (en) 2024-03-26 2026-03-05 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2025202287A1 (en) 2024-03-26 2025-10-02 Resolution Therapeutics Limited Method of producing macrophages
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025210520A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for inducing an immunological response
WO2025210521A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for stimulating t cells
WO2025213131A1 (en) 2024-04-05 2025-10-09 BioNTech SE Rna compositions for delivery of orthopox antigens and related methods
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2025217264A1 (en) 2024-04-10 2025-10-16 Acuitas Therapeutics, Inc. Cationic lipid compounds for use in lipid nanoparticles
WO2025219491A1 (en) 2024-04-17 2025-10-23 Global Life Sciences Solutions Canada Ulc Method and composition for hdr template dna delivery
WO2025219528A1 (en) 2024-04-17 2025-10-23 Global Life Sciences Solutions Canada Ulc Non-destructive plasmid delivery to immune cells
WO2025219199A1 (en) 2024-04-19 2025-10-23 Evonik Operations Gmbh Process for producing nanocarriers and/or nanoformulations
EP4677108A1 (en) 2024-04-22 2026-01-14 Basecamp Research Ltd Method and compositions for detecting off-target editing
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2025231114A1 (en) 2024-05-01 2025-11-06 Acuitas Therapeutics, Inc. Method of using lipid nanoparticles for intramuscular delivery
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
WO2025240833A1 (en) 2024-05-17 2025-11-20 Acuitas Therapeutics, Inc. Galnac lipid compounds for use in lipid nanoparticles
WO2025250808A1 (en) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Anti-crispr delivery compositions and methods
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026003754A1 (en) 2024-06-25 2026-01-02 Life Edit Therapeutics, Inc. Novel reverse transcriptases and uses thereof
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026015882A1 (en) 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026020171A2 (en) 2024-07-19 2026-01-22 Aera Therapeutics, Inc. Chimeric antigen receptor constructs
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026064512A1 (en) 2024-09-18 2026-03-26 Generation Bio Co. Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
WO2026072773A1 (en) 2024-09-27 2026-04-02 Pfizer Inc. Compositions and methods for reduction of double-stranded rna
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing
WO2026078579A1 (en) 2024-10-08 2026-04-16 Precision Biosciences, Inc. Methods and compositions for treating hepatitis b virus-related conditions
WO2026078565A1 (en) 2024-10-10 2026-04-16 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems
WO2026083241A1 (en) 2024-10-15 2026-04-23 Genevant Sciences Gmbh Ionizable lipids comprising n,n-substituted hydroxylamine esters
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
DE3068743D1 (en) 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4598051A (en) 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
GR77320B (https=) * 1980-12-22 1984-09-11 Procter & Gamble
US4394372A (en) 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4602354A (en) 1983-01-10 1986-07-22 Ncr Corporation X-and-OR memory array
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
JPS607932A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソーム懸濁液およびその製法
US5550289A (en) 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
JPH03126211A (ja) 1989-10-12 1991-05-29 Nippon Chemicon Corp 電解コンデンサ用電解液
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013580A1 (de) 1990-04-24 1991-10-31 Schering Ag Verfahren zur herstellung von wirkstoffhaltigen waessrigen liposomensuspensionen
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JPH0665382B2 (ja) * 1991-03-20 1994-08-24 雪印乳業株式会社 リポソーム調製装置とその装置を使用するリポソーム調製方法
JP2774417B2 (ja) 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 ペプチド骨格を有する分枝鎖型糖複合体及び微粒子キャリヤー
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US6001644A (en) 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993017125A1 (en) 1992-02-19 1993-09-02 Baylor College Of Medicine Oligonucleotide modulation of cell growth
ATE194767T1 (de) * 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
JP2854203B2 (ja) 1992-09-03 1999-02-03 株式会社ディ・ディ・エス研究所 リポソームの製造法
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
JP3479535B2 (ja) 1993-07-08 2003-12-15 ザ リポソーム カンパニー、インコーポレーテッド リポソームの粒径を制御する方法
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
CA2194221C (en) 1994-06-22 2001-01-02 Megabios Corporation Cationic amphiphiles
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1996040726A1 (en) 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6007838A (en) * 1995-06-07 1999-12-28 The United States Of America As Represented By The Secretary Of The Army Process for making liposome preparation
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0840744A4 (en) 1995-06-07 1999-03-10 Genta Inc CATIONIC LIPIDS BASED ON PHOSPHONIC ACID
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
US6330349B1 (en) 1995-11-30 2001-12-11 Chromavision Medical Systems, Inc. Automated method for image analysis of residual protein
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
DK0807431T3 (da) * 1996-05-14 2004-07-26 Dsm Ip Assets Bv Fremgangsmåde til fremstilling af carotenoidpræparater
US6284267B1 (en) 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6034135A (en) 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US5877220A (en) 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
AU7490098A (en) 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
JP2002508765A (ja) * 1997-06-23 2002-03-19 アルザ コーポレイション リポソーム被包ポリヌクレオチド組成物および方法
US20030083272A1 (en) 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy
CA2309727C (en) 1997-10-10 2012-12-04 Inex Pharmaceuticals Corporation Methods for encapsulating nucleic acids in lipid bilayers
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
CA2271582A1 (en) 1998-05-14 1999-11-14 Sean C. Semple Method for administration of therapeutic agents, including antisense, with repeat dosing
US20030044454A1 (en) 1998-06-30 2003-03-06 Masaru Fukui Compositions containing liposomes and/or emulsions and process for the preparation thereof
AU747597B2 (en) 1998-07-20 2002-05-16 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
WO2000029103A1 (en) 1998-11-13 2000-05-25 Optime Therapeutics, Inc. Method and apparatus for liposome production
US6649780B1 (en) 1998-12-22 2003-11-18 Valentis, Inc. Cationic lipids
JP5117648B2 (ja) 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア カチオン性ｐｅｇ脂質および使用方法。
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US20010048940A1 (en) 1999-06-18 2001-12-06 Jennifer D. Tousignant Cationic amphiphile micellar complexes
DK1198490T3 (da) 1999-07-14 2006-06-19 Alza Corp Neutral lipopolymer og liposomsammensætninger indeholdende samme
BR0012624B1 (pt) 1999-07-15 2011-08-09 métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos.
US6242188B1 (en) * 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
EP1471870B1 (en) 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
AU2001275423B2 (en) 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
ATE354350T1 (de) 2000-10-25 2007-03-15 Univ British Columbia Lipidformulierungen zur zielgerichteten abgabe
EP1337664A4 (en) 2000-10-27 2005-01-19 Invitrogen Corp METHOD FOR INTRODUCING ANTISENSE OLIGONUCLEOTIDES IN EUKARYOTIC CELLS
EP1203614A1 (de) * 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
AU2002219998B2 (en) * 2000-12-01 2006-03-02 Biomira, Inc. Preparation of large liposomes by infusion into peg
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
ES2295351T3 (es) 2001-04-21 2008-04-16 Curevac Gmbh Dispositivo para la inyeccion de rnam.
US20040142892A1 (en) 2001-04-30 2004-07-22 The University Of British Columbia Autogene nucleic acids encoding a secretable RNA polymerase
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
ES2340499T3 (es) 2001-06-05 2010-06-04 Curevac Gmbh Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado.
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2003059381A2 (en) 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
JP2007524349A (ja) 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US7067169B2 (en) 2003-06-04 2006-06-27 Chemat Technology Inc. Coated implants and methods of coating
EP1638919B1 (en) 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1664316B1 (en) 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
EP1773857A4 (en) 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
WO2007086881A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US20060228406A1 (en) 2005-03-17 2006-10-12 Invitrogen Corporation Transfection reagent for non-adherent suspension cells
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2281041B1 (en) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Silencing of csn5 gene expression using interfering rna
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CN103380113B (zh) 2010-11-15 2018-03-30 生命科技公司 含胺的转染试剂及其制备和使用方法
JP6620093B2 (ja) 2013-07-23 2019-12-11 アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ メッセンジャーｒｎａを送達するための組成物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013067657A (ja) * 2002-06-28 2013-04-18 Protiva Biotherapeutics Ltd リポソーム製造方法および装置

Also Published As

Publication number Publication date
DK1519714T3 (da) 2011-01-31
AU2009212823A1 (en) 2009-09-17
US20140044772A1 (en) 2014-02-13
ATE485031T1 (de) 2010-11-15
JP2010184947A (ja) 2010-08-26
AU2003245160B2 (en) 2009-09-24
ES2354607T3 (es) 2011-03-16
AU2003245160A1 (en) 2004-01-19
US11298320B2 (en) 2022-04-12
US20200268664A1 (en) 2020-08-27
EP1519714B1 (en) 2010-10-20
JP2013067657A (ja) 2013-04-18
EP2338478A1 (en) 2011-06-29
EP1519714A1 (en) 2005-04-06
US8329070B2 (en) 2012-12-11
CA2491164A1 (en) 2004-01-08
JP2016199585A (ja) 2016-12-01
US20040142025A1 (en) 2004-07-22
US20190167586A1 (en) 2019-06-06
DE60334618D1 (de) 2010-12-02
CA2491164C (en) 2012-05-08
US20210267891A1 (en) 2021-09-02
JP2016172778A (ja) 2016-09-29
JP2005538967A (ja) 2005-12-22
EP2823809B1 (en) 2016-11-02
US20140294937A1 (en) 2014-10-02
US9504651B2 (en) 2016-11-29
US20210275454A1 (en) 2021-09-09
US7901708B2 (en) 2011-03-08
US9492386B2 (en) 2016-11-15
WO2004002453A1 (en) 2004-01-08
US11318098B2 (en) 2022-05-03
EP2338478B1 (en) 2014-07-23
EP2823809A1 (en) 2015-01-14
US20110216622A1 (en) 2011-09-08
AU2009212823B2 (en) 2011-09-01
JP5192515B2 (ja) 2013-05-08
US20170258719A1 (en) 2017-09-14
US20210275455A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
JP4722481B2 (ja) リポソーム製造方法および装置
JP5639338B2 (ja) リポソームの製造システムおよび製造方法
EP2558074B1 (en) Preparation of lipid nanoparticles

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100604

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110323

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110406

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4722481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term